Regulatory Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval pharminent August 17, 2026
News BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple Myeloma pharminent August 14, 2026
Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026
News Eli Lilly Files Six Lawsuits to Combat Illegal Retatrutide Black Market pharminent August 12, 2026
M&A / Deals Sentynl bets up to $475M in licensing deal for Mereo’s rare lung disease asset pharminent August 12, 2026
News Trump Executive Order Strips Seven Vaccines From Childhood Immunization Recommendations pharminent August 11, 2026
Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026
Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026
Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
Regulatory UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition pharminent August 11, 2026
Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026
M&A / Deals Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront pharminent August 11, 2026
Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy pharminent August 7, 2026
M&A / Deals Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments pharminent August 7, 2026
News FDA Approves Moderna’s mFlusiva, the First mRNA-Based Seasonal Flu Vaccine pharminent August 6, 2026
News Eli Lilly Smashes Q2 Estimates, Raises 2026 Guidance to $85–$87B on GLP-1 Surge pharminent August 5, 2026
Pipeline Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts pharminent August 5, 2026
Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026
Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026
News Pfizer Axes Ex-Metsera Obesity Asset and GIPR Prospect in Quarterly Pipeline Clearout pharminent August 4, 2026
M&A / Deals Supernus and Indivior merge to create scaled, CNS-focused entity pharminent August 4, 2026
News AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger Talks pharminent August 3, 2026
M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026
News Novo Nordisk’s Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular Trial pharminent August 1, 2026
Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026